| abstract |
2-benzylpyridazinone derivatives of formula (I) are disclosed, wherein the variables R1, R2, R3, R4 and R4' are as defined in the specification. These compounds are inhibitors of tyrosine kinases, in particular Met kinase, and can be used, inter alia, for the treatment of solid tumours that originate from the group of tumours of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, the larynx, the lung, the group monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma. |